AI assistant
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2025
Nov 25, 2025
31542_dirs_2025-11-24_df1252c4-9d02-4566-af94-d76942d88648.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2025-11-20
Reporting Person: DENKHAUS DONALD A (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-21 | Common Stock, par value $0.001 per share | M | 947 | — | Acquired | 496026 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | Options to purchase common stock | $22.77 | A | 18115 | Acquired | 2032-11-20 | Common Stock (18115) | Direct |
| 2025-11-20 | Restricted Stock Units | $ | A | 5468 | Acquired | Common Stock (5468) | Direct | |
| 2025-11-21 | Restricted Stock Units | $ | M | 947 | Disposed | Common Stock (947) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
F3: Shares of common stock will be delivered to the Reporting Person upon vesting.
F4: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
F5: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.